Skip to main content

Table 1 Algorithms used to calculate hepatic steatosis index and fibrosis scores

From: The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

Hepatitis Steatosis Index

\(8\times\left(\text{ALT}\left[\text{U/l}\right]/\text{AST}\left[\text{U/l}\right]\right)+\text{BMI}\left[\text{kg}/\mathrm{m}^2\right]\left(+2\,\text{if type 2 diabetes,}+2\,\text{if female}\right)\) 

Fibrosis-4 index (FIB-4)

\(\text{Age}\left[\text{years}\right]\times\text{AST}\left[\text{U/l}\right]/\left(\text{platelets}\left[\times10^9/\mathrm{L}\right]\times\sqrt{}\left(\text{ALT}\left[\text{U/l}\right]\right)\right)\) 

NAFLD fibrosis score (NFS)

 \(-1.675+0.037\times\text{age}\left[\text{years}\right]+0.094\times\text{BMI}\left[\mathrm{kg}/\mathrm{m}^2\right]+1.13\times\left(\text{IFG or diabetes [yes = 1, no = 0]}\right)+0.99\times\text{AST}\left[\text{U/l}\right]/\text{ALT}\left[\text{U/l}\right]-0.013\times\text{platelets}\left[10^9/\mathrm{L}\right]-0.66\times\text{albumin}\left[\text{g/dl}\right]\) 

  1. ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, IFG impaired fasting glucose